| OPERATING ROOM |
Healthios clients can access exclusive project material and proprietary content in a secure and consistent environment.
CLIENTS… log-in»
Welcome to Kidney Disease!
From late breaking news to key company press releases, from financings to who is investing, you will find it here.
Sector Performance ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Companies |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investors |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calendar |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Executive Summary01.30.08
“Flight to Safety or Better Performance” Baxter announced earnings last week and showed strong financial results for the fourth quarter that met or exceeded previously iss... more»Leadership Review
Roche Holding AG announced resignation of Franz Humer as chief executive. Humer, 61, led Roche's drive to develop a leading line of cancer drugs. As he handed over his duties to Severin Schwan, former... more»
Roche Holding AG announced resignation of Franz Humer as chief executive. Humer, 61, led Roche's drive to develop a leading line of cancer drugs. As he handed over his duties to Severin Schwan, former... more»
Mergers & Acquisitions
Takeda Pharmaceutical Co. entered into a sale and purchase agreement to acquire Amgen K.K. from Amgen, Inc. on February 1, 2008. Terms of the transaction were not disclosed. Under the terms of the agr... more»
Takeda Pharmaceutical Co. entered into a sale and purchase agreement to acquire Amgen K.K. from Amgen, Inc. on February 1, 2008. Terms of the transaction were not disclosed. Under the terms of the agr... more»
Corporate Finance
Angiotech Pharmaceuticals Inc. announced the filing of its audited consolidated financial statements and Management's Discussion and Analysis for the year ended December 31, 2007 and the restatement o... more»
Angiotech Pharmaceuticals Inc. announced the filing of its audited consolidated financial statements and Management's Discussion and Analysis for the year ended December 31, 2007 and the restatement o... more»
News & Events
Nabi Biopharmaceuticals (Nasdaq:NABI) announced today a settlement of the patent infringement case against Roxane Laboratories that involved Nabi's former product, PhosLo(r) (calcium acetate) GelCaps.... more»
Nabi Biopharmaceuticals (Nasdaq:NABI) announced today a settlement of the patent infringement case against Roxane Laboratories that involved Nabi's former product, PhosLo(r) (calcium acetate) GelCaps.... more»
Earnings Announcements
Rockwell Medical Technologies Inc. reported record fourth quarter 2007 sales of $11.95 million, up 29.5% as compared to $9.2 million for the same period of 2006. Loss for the fourth quarter was $1,162... more»
Rockwell Medical Technologies Inc. reported record fourth quarter 2007 sales of $11.95 million, up 29.5% as compared to $9.2 million for the same period of 2006. Loss for the fourth quarter was $1,162... more»
Strategic Development
Amgen Inc. and Takeda Pharmaceutical Company Limited have entered into an agreement under which Takeda will develop and commercialize for the Japanese market up to 13 molecules from Amgen's pipeline, ... more»
Amgen Inc. and Takeda Pharmaceutical Company Limited have entered into an agreement under which Takeda will develop and commercialize for the Japanese market up to 13 molecules from Amgen's pipeline, ... more»
Clinical & Regulatory
ProMetic Life Sciences Inc. announced favorable top-line findings from the third cohort in its Phase II trial with PBI-1402 in patients with chemotherapy-induced anemia. Analysis of the compiled data ... more»
ProMetic Life Sciences Inc. announced favorable top-line findings from the third cohort in its Phase II trial with PBI-1402 in patients with chemotherapy-induced anemia. Analysis of the compiled data ... more»
